BioSpace News Archive

Business

Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Daniel O’Connor as Chief Executive Officer.

November 1, 2022
·
5 min read
Deals

OmniAb Announces Completion of Spin-Off and Business Combination

OmniAb, Inc. announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated and the subsequent business combination with Avista Public Acquisition Corp. II, resulting in OmniAb becoming an independent publicly traded company.

November 1, 2022
·
8 min read
Business

Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the third quarter ended September 30, 2022 and recent corporate highlights.

November 1, 2022
·
14 min read
Drug Development

Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022

Sonnet BioTherapeutics Holdings, Inc. announced that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010 in oncology patients and its SB102 clinical study with SON-1010 in healthy volunteers on Wednesday, November 2, 2022 at 8:30 am ET.

November 1, 2022
·
4 min read
Business

Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

November 1, 2022
·
20 min read
Business

Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα

Exelixis, Inc. and Sairopa B.V. announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.

November 1, 2022
·
9 min read
Biotech Beach

Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences in November 2022

Pipeline Therapeutics announced that management will present at the following investor conferences during November 2022.

November 1, 2022
·
1 min read
Business

Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical

Focal Medical, Inc., a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative local drug delivery technology platform, announced the appointment of Michael Aldridge as the Company’s new Chief Executive Officer.

November 1, 2022
·
5 min read
Business

Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK) today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.

November 1, 2022
·
2 min read
Business

Novavax Appoints Rick Rodgers to Board of Directors

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the appointment of Richard Rodgers, MBA to its board as an independent director.

November 1, 2022
·
5 min read